Kristóf Madarász

Mr. Kristóf Madarász

University of Debrecen, Debrecen, Hajdú-Bihar, Hungary
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
YCYi-Che Chang Chien
Yi-Che Chang Chien
Kristóf MadarászKristóf Madarász
Kristóf Madarász
SCSzilvia Lilla Csoma
Szilvia Lilla Csoma
János MótyánJános Mótyán
János Mótyán
HHHsuan-Ying Huang
Hsuan-Ying Huang
AMAttila Mokánszki
Attila Mokánszki
BCOR (BCL6 corepressor)-rearranged sarcomas (BRSs) are a heterogeneous group of sarcomas previously classified as part of the group of “atypical Ewing” or “Ewing-like” sarcomas, without the prototypical ESWR1 gene translocation. Due to their similar morphology and histopathological features, diagnosis is challenging. The most common genetic aberrations are BCOR-CCNB3 fusion and BCOR internal tandem duplication (ITD). Recently, various new fusion partners of BCOR have been documented, such as MAML3, ZC3H7B, RGAG1, and KMT2D, further increasing the complexity of such tumor entities, although the molecular pathogenetic mechanism remains to be elucidated. Here, we present an index case of intrathoracic BRS that carried a novel BCOR-CLGN (calmegin) gene fusion, exhibited by a 52-year-old female diagnosed initially by immunohistochemistry due to the positivity of a BCOR stain; the fusion was identified by next-generation sequencing and was confirmed by Sanger sequencing. In silico protein analysis was performed to demonstrate the 3D structure of the chimera protein. The physicochemical properties of the fusion protein sequence were calculated using the ProtParam web-server tool. Our finding further broadens the fusion partner gene spectrum of BRS. Due to the heterogeneity, molecular ancillary tests serve as powerful tools to discover these unusual variants, and an in silico analysis of the fusion protein offers an appropriate approach toward understanding the exact pathogenesis of such a rare variant.

2 November 2022 in Cells
Verified
Journal Article
Open access
PDF file
Kristóf MadarászKristóf Madarász
Kristóf Madarász
János MótyánJános Mótyán
János Mótyán
JBJudit Bedekovicsi
Judit Bedekovicsi
ZMZsófia Miltényi
Zsófia Miltényi
AUAniko Ujfalusi
Aniko Ujfalusi
AMAttila Mokánszki
Attila Mokánszki
Background: Mutation of the TP53 gene is one of the major drivers of myelodysplastic neoplasias (MDS) and acute myeloid leukemia with myelodysplasia-related changes (AML-MR). TP53 mutations present in these hematopoietic malignancies form a distinct molecular genetic cluster with a worse prognosis than without the alteration. However, besides well-characterized hot-spot variants, a significant proportion of TP53 alterations are of uncertain clinical significance. Methods: To enlighten so far unknown aspects, bone-marrow samples from altogether 77 patients are analyzed retrospectively with the diagnosis of AML-MR (26 cases), MDS-IB (12 cases), and MDS-LB (39 cases) according to WHO 2022 guidelines. Next-generation sequencing results are correlated with histological, cytogenetic, and survival data. Results: Twenty out of the 30 TP53 mutation types detected by NGS are not categorized in current public databases; thus, their clinical significance remained mysterious. Because of the interpretation difficulties and the absence of clinical correlations, pathogenicity is established based on in silico approaches. The 12 pathogenicity classification systems, as well as protein stability, protein–DNA, protein–protein interaction, and post-translational modification analyses are applied. We found statistically significant differences between AML/MDS groups considering p53 pathogenicity, protein structural changes, and overall survival. The largest number of abnormalities with the most severe consequences are found in AML-MR cases. Conclusions: These molecular and in silico protein data further support that MDS with increased-blast (MDS-IB) is an intermediate group between AML-MR and MDS with low-blast (MDS-LB) patients, which frequently progresses to AML and is therefore considered a pre-leukemic condition.

25 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SCSzilvia Lilla Csoma
Szilvia Lilla Csoma
Kristóf MadarászKristóf Madarász
Kristóf Madarász
YCYi-Che Chang Chien
Yi-Che Chang Chien
GEGabriella Emri
Gabriella Emri
JBJudit Bedekovicsi
Judit Bedekovicsi
AMAttila Mokánszki
Attila Mokánszki
Here, we investigate the correlation and statistical analyses between histological staging and molecular alterations in tumor-derived (tdDNA) and cell-free DNA (cfDNA) obtained from early-stage primary cutaneous melanoma (PCM) patients using digital PCR (dPCR) for the detection of the BRAF p.V600E somatic pathogenic variant. In the prospective study, a total of 68 plasma and paired tdDNA samples, and in the retrospective cohort, a total of 100 tdDNA samples were analyzed using dPCR and reverse hybridization StripAssay. The Breslow depth (BD) and Clark level were applied to categorize the study population. Our results demonstrate that dPCR is a highly sensitive and specific method for the detection of BRAF p.V600E somatic variants in cfDNA samples from PCM patients. A strong correlation was detected between BD and cfDNA concentration in all mutant and negative cases, between the tdDNA concentration and the tumor-derived variant allele frequency (VAF) of BRAF p.V600E, between the tdVAF and the cfVAF in all cases, and between the cfDNA and cfVAF in mutant cases. The tdVAF and cfVAF of BRAF p.V600E and cfDNA concentration were the highest in Clark’s V category. The cfDNA concentration was statistically significantly higher in Clark’s III, IV, and V groups compared to cases with a better prognosis. It can also be explained by the fact that cases with a more advanced stage classification release more cfDNA into the peripheral circulation.

14 April 2025 in Computers in Biology and Medicine
Verified
Journal Article
Open access
Kristóf MadarászKristóf Madarász
Kristóf Madarász
János MótyánJános Mótyán
János Mótyán
YCYi-Che Chang Chien
Yi-Che Chang Chien
JBJudit Bedekovicsi
Judit Bedekovicsi
SCSzilvia Lilla Csoma
Szilvia Lilla Csoma
AMAttila Mokánszki
Attila Mokánszki
BCOR (BCL-6 corepressor) rearranged small round cell sarcoma (BRS) represents an uncommon soft tissue malignancy, frequently characterized by the BCOR::CCNB3 fusion. Other noteworthy fusions include BCOR::MAML3, BCOR::CLGN, BCOR::MAML1, ZC3H7B::BCOR, KMT2D::BCOR, CIITA::BCOR, RTL9::BCOR, and AHR::BCOR. The BCOR gene plays a pivotal role in the Polycomb Repressive Complex 1 (PRC1), essential for histone modification and gene silencing. It interfaces with the Polycomb group RING finger homolog (PCGF1). This study employed comprehensive in silico methodologies to investigate the structural and functional effects of BCOR fusion events in BRS. The analysis revealed significant alterations in the domain architecture of BCOR, which resulted in the loss of BCL6-regulated transcriptional repression. Furthermore, IUPred3 prediction indicated a significant increase in disorder in the C-terminal regions of the BCOR in the fusion proteins. A detailed analysis of the physicochemical properties by ProtParam revealed a decrease in isoelectric point, stability, and hydrophobicity. The analysis of protein structures predicted by AlphaFold3 using the PRODIGY algorithm revealed statistically significant deviations in binding affinities for BCOR-PCGF1 dimers and a non-canonical PRC1 variant tetramer compared to the wild-type BCOR. The findings provide a comprehensive summary and elucidation of the fusion proteome associated with BRS, suggesting a substantial impact on the stability and functionality of the fusion proteins, thereby contributing to the oncogenic mechanisms underlying BRS. In this study, we provide the first compilation and comparative analysis of the known BCOR fusions of BRS and introduce a new in silico approach to enhance a better understanding of the molecular basis of BRS.

21 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
Kristóf MadarászKristóf Madarász
Kristóf Madarász
János MótyánJános Mótyán
János Mótyán
YCYi-Che Chang Chien
Yi-Che Chang Chien
JBJudit Bedekovicsi
Judit Bedekovicsi
SCSzilvia Lilla Csoma
Szilvia Lilla Csoma
AMAttila Mokánszki
Attila Mokánszki
BCOR (BCL-6 corepressor)-rearranged small round cell sarcoma (BRS) is a rare soft tissue tumor, mostly featuring the BCOR :: CCNB3 fusion, with other fusions like BCOR :: MAML3 , BCOR :: CLGN , ZC3H7B :: BCOR , KMT2D :: BCOR , CIITA :: BCOR , and RTL9 - BCOR also reported. BCOR, a Polycomb Repressive Complex 1 (PRC1) component, influences histone modifications. It dimerizes with Polycomb group RING finger homolog (PCGF1) via its PCGF ubiquitin-like fold discriminator (PUFD) domain interacting with PCGF1’s RING finger and WD40-associated ubiquitin-like (RAWUL) domain. We used various in silico tools to explore the impact of fusion events on BCOR’s functionality and RAWUL-PUFD dimer binding affinity. Changes were found in the domain landscapes, physicochemical properties, GO terms and significant increases in the disordered regions within the PUFD domain of the fusion proteins. Structural predictions indicated modified intermolecular contacts (ICs) and a significant reduction in binding affinity in fusion protein RAWUL-PUFD dimers. These findings align with expression data showing PRC1-regulated gene upregulation in BRS, likely due to reduced RAWUL-PUFD binding affinity, impacting dimer formation and PRC1 assembly. Our findings enhance the understanding of BRS oncogenesis and identify potential therapeutic targets.

4 September 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
JBJudit Bedekovicsi
Judit Bedekovicsi
Kristóf MadarászKristóf Madarász
Kristóf Madarász
AMAttila Mokánszki
Attila Mokánszki
SMSarolta Molnár
Sarolta Molnár
ÁMÁgnes Mester
Ágnes Mester
GMGábor Méhes
Gábor Méhes
Background: TP53 alterations have a significant prognostic effect in myeloid neoplasms. Our objective was to investigate the TP53 gene mutation status, p53 protein expression, and their re-lationship in dysplasia-related myeloid neoplasms with varying levels of myeloblast counts. Methods: 76 bone marrow biopsy samples with different blast counts were analyzed. Total and strong (3+) p53 expression was determined. Dual immunohistochemical staining was performed to determine the cell population associated with p53 expression. NGS analysis was performed using the Accel-Amplicon Comprehensive TP53 panel. Results: Both p53 expression and TP53 VAF showed a significant correlation with the myeloblast ratio (p<0.0001), however, p53 expres-sion was present in other cell lineages as well. The VAF value exhibited a significant correlation with p53 expression. A high specificity (0.9800) was observed for TP53 mutation using the ≥10% strong (3+) p53 cut-off value, although the sensitivity (0.4231) was low. Conclusion: Strong (3+) p53 expression using a ≥10% cut-off value accurately predicts TP53 mutation but doesn't reveal the allelic state. The p53 expression is significantly influenced by myeloblast count, and histo-logical interpretation should consider the presence of intermixed non-neoplastic marrow cells with varying physiological p53 expression.